---
title: "Saroglitazar in Primary biliary cholangitis: Clinical evidence"
description: "Formulary evidence on Saroglitazar in Primary biliary cholangitis: Clinical evidence. Covers EPICS-III, EPICS-IV, EPICS-V, EPICS, Open-label single-arm study, SARO.23.002, and 9 further headings. 172 evidence topics quoted from 30 sources."
canonical: "https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/clinical-evidence"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Saroglitazar in Primary biliary cholangitis: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 EPICS-III

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Biochemical-response objective

> “biochemical response”

Source: [EU Clinical Trials Register EudraCT 2022-001634-10](https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-001634-10/ES)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Protocol-listed study region

> “United States”

Source: [EU Clinical Trials Register EudraCT 2022-001634-10](https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-001634-10/ES)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### EPICS-III: NCT05133336

> “A multicenter, randomized, double-blind, placebo controlled, phase 2b/3 study to evaluate the efficacy and safety of saroglitazar magnesium”

Source: [Zydus Therapeutics PBC clinical trials page](https://zydustx.com/clinical-trials/pbc-clinical-trials/)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### EPICS-III: inclusion-criteria excerpts

| Criterion | Quoted protocol text |
| --- | --- |
| UDCA-treated population | “Subjects on ursodeoxycholic acid (UDCA) for at least 12 months” |
| UDCA-intolerant population | “Subjects who are unable to tolerate UDCA” |
| ALP threshold | “ALP ≥ 1.67 x ULN” |

Source: [EU Clinical Trials Register EudraCT 2022-001634-10](https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-001634-10/ES)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Investigational dosage and administration

> “Saroglitazar Magnesium 1 mg tablet orally administered once daily in the morning before breakfast without food”
> “52 weeks”

Source: [ClinicalTrials.gov NCT05133336](https://clinicaltrials.gov/study/NCT05133336)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using ALP and Bilirubin Biochemical Response as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### EPICS-III: composite biochemical-response endpoint

| Component | Quoted definition |
| --- | --- |
| ALP threshold | “alkaline phosphatase (ALP) <1.67x upper limit of normal (ULN)” |
| ALP decrease relative to baseline | “≥15%” |
| Total bilirubin criterion | “total bilirubin ≤ ULN” |
| Gilbert’s syndrome alternative | “direct bilirubin ≤ULN in patients with known Gilbert's syndrome” |
| Assessment | “52 weeks” |

Source: [Zydus Therapeutics (2025)](https://www.prnewswire.com/news-releases/zydus-therapeutics-reports-positive-topline-results-from-epics-iii-phase-2b3-trial-of-saroglitazar-magnesium-in-patients-with-primary-biliary-cholangitis-302542014.html)

<a id="topic-3.1.1.6.1-2"></a>

###### Prognostic association of the biochemical markers

> “Combining levels of alkaline phosphatase and bilirubin increased the ability to predict patient survival times.”

Source: [Lammers et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25160979/)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Protocol-planned enrollment

| Population | Planned participants |
| --- | --- |
| Whole phase 2b/3 protocol | “192” |

Source: [EU Clinical Trials Register EudraCT 2022-001634-10](https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-001634-10/ES)

<a id="topic-3.1.1.7.1-2"></a>

###### Phase 3 enrollment reported in the topline release

| Population | Reported participants |
| --- | --- |
| Randomized phase 3 cohort | “149” |

Source: [Zydus Therapeutics (2025)](https://www.prnewswire.com/news-releases/zydus-therapeutics-reports-positive-topline-results-from-epics-iii-phase-2b3-trial-of-saroglitazar-magnesium-in-patients-with-primary-biliary-cholangitis-302542014.html)

<a id="topic-3.1.1.7.1-3"></a>

###### EPICS-III: phase III results

| Endpoint or population | Saroglitazar | Placebo |
| --- | --- | --- |
| Reported trial N | “148” | |

Source: [Zydus Lifesciences NDA priority review announcement (2026)](https://zyduslife.com/investor/admin/uploads/21/83/Press-Release_Zydus-Therapeutics-NDA-for-Saroglitazar-to-treat.pdf)

<a id="topic-3.1.1.7.1-4"></a>

###### Registry-reported enrollment across the combined study

| Population | Reported participants |
| --- | --- |
| Combined study enrollment | “196” |

Source: [Veeva Systems EPICS-III study page](https://ctv.veeva.com/study/saroglitazar-magnesium-for-treatment-of-primary-biliary-cholangitis)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Phase 3 baseline ALP

| Characteristic | Saroglitazar | Placebo |
| --- | --- | --- |
| Mean ALP, U/L | “363” | “317.2” |

Source: [Zydus Therapeutics (2026)](https://www.prnewswire.com/news-releases/zydus-therapeutics-new-drug-application-nda-for-saroglitazar-to-treat-primary-biliary-cholangitis-pbc-granted-priority-review-by-the-us-fda-302784488.html)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### EPICS-III: phase III biochemical results

| Endpoint or population | Saroglitazar | Placebo |
| --- | --- | --- |
| Biochemical response at Week 52 | “56.7%” | “9.8%” |
| ALP percentage change from baseline at Week 52 | “-33.5%” | “+6.5%” |

Source: [Zydus Lifesciences NDA priority review announcement (2026)](https://zyduslife.com/investor/admin/uploads/21/83/Press-Release_Zydus-Therapeutics-NDA-for-Saroglitazar-to-treat.pdf)

<a id="topic-3.1.1.8.3-2"></a>

###### EPICS-III: treatment differences

| Treatment difference | Quoted result |
| --- | --- |
| Biochemical response | “48% (95% CI: 35.3, 60.8) (p < 0.001)” |
| Least-squares mean ALP change | “-124.1 U/L (-40.1%)” |

Source: [Zydus Lifesciences NDA priority review announcement (2026)](https://zyduslife.com/investor/admin/uploads/21/83/Press-Release_Zydus-Therapeutics-NDA-for-Saroglitazar-to-treat.pdf)

Additional sources: [Vuppalanchi et al. (2026)](https://www.researchgate.net/publication/405332836_LBO-001_A_phase_2b3_trial_of_saroglitazar_in_primary_biliary_cholangitis_EPICS_III)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

###### EPICS-III: week 52 pruritus results

| Endpoint or population | Saroglitazar | Placebo |
| --- | --- | --- |
| Change in 5-D Itch Total score at Week 52 | “-4.6” | “-4.4” |

Source: [Zydus Lifesciences NDA priority review announcement (2026)](https://zyduslife.com/investor/admin/uploads/21/83/Press-Release_Zydus-Therapeutics-NDA-for-Saroglitazar-to-treat.pdf)

<a id="topic-3.1.1.8.4-2"></a>

###### EPICS-III: pruritus

> “statistically significant improvements observed at six months, although significance was not maintained at the 12-month assessment.”

Source: [EASL Congress (2026)](https://www.easlcongress.eu/wp-content/uploads/2026/05/Media-Release_scientific-2026_28-May_none-1.pdf)

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### EPICS-III: serious adverse events

| Endpoint or population | Saroglitazar | Placebo |
| --- | --- | --- |
| Serious adverse events | “6.3%” | “11.1%” |

Source: [Zydus Lifesciences NDA priority review announcement (2026)](https://zyduslife.com/investor/admin/uploads/21/83/Press-Release_Zydus-Therapeutics-NDA-for-Saroglitazar-to-treat.pdf)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

The primary endpoint is a biochemical surrogate, not a direct measure of transplantation or survival. The topline release reports 149 randomized participants, whereas the later NDA-supporting report gives a phase 3 trial population of 148; these totals are not reconciled in the retrieved evidence. The combined-study registry enrollment of 196 is a different population. Pruritus improvement was not statistically significant at 12 months.

Source: [Zydus Therapeutics (2025)](https://www.prnewswire.com/news-releases/zydus-therapeutics-reports-positive-topline-results-from-epics-iii-phase-2b3-trial-of-saroglitazar-magnesium-in-patients-with-primary-biliary-cholangitis-302542014.html); [Zydus Lifesciences NDA priority review announcement (2026)](https://zyduslife.com/investor/admin/uploads/21/83/Press-Release_Zydus-Therapeutics-NDA-for-Saroglitazar-to-treat.pdf); [Veeva Systems EPICS-III study page](https://ctv.veeva.com/study/saroglitazar-magnesium-for-treatment-of-primary-biliary-cholangitis); [EASL Congress (2026)](https://www.easlcongress.eu/wp-content/uploads/2026/05/Media-Release_scientific-2026_28-May_none-1.pdf); [Lammers et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25160979/)

<a id="heading-3.1.2"></a>

#### 3.1.2 EPICS-IV

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### ALP-normalization objective

> “normalization of ALP”

Source: [Veeva Systems EPICS-IV study page](https://ctv.veeva.com/study/study-of-saroglitazar-magnesium-for-pbc-patients-with-incomplete-response-or-intolerant-to-udca-ther)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

Additional sources: [Indiana University](https://research-studies.allinforhealth.info/us/en/listing/14117/a-double-blind-placebo-controlled-randomized-NCT07424677-774/)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Randomized, double-blind, placebo-controlled phase 3 design

> “A Double-blind, Placebo-controlled, Randomized, Phase 3 Study”

Source: [Veeva Systems EPICS-IV study page](https://ctv.veeva.com/study/study-of-saroglitazar-magnesium-for-pbc-patients-with-incomplete-response-or-intolerant-to-udca-ther)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### ALP-based eligibility

| Criterion | Quoted criterion |
| --- | --- |
| Screening ALP | “ALP > ULN to < 1.67xULN” |

Source: [Veeva Systems EPICS-IV study page](https://ctv.veeva.com/study/study-of-saroglitazar-magnesium-for-pbc-patients-with-incomplete-response-or-intolerant-to-udca-ther)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Saroglitazar magnesium: oral morning dosing

> “1 mg, once daily”

Source: [Veeva Systems EPICS-IV study page](https://ctv.veeva.com/study/study-of-saroglitazar-magnesium-for-pbc-patients-with-incomplete-response-or-intolerant-to-udca-ther)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using ALP Normalization as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### ALP as a prognostic marker

> “Combining levels of alkaline phosphatase and bilirubin increased the ability to predict patient survival times.”

Source: [Lammers et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25160979/)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Planned enrollment

| Population | Estimated participants |
| --- | --- |
| Randomized study | “89” |

Source: [Veeva Systems EPICS-IV study page](https://ctv.veeva.com/study/study-of-saroglitazar-magnesium-for-pbc-patients-with-incomplete-response-or-intolerant-to-udca-ther)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

No evidence found.

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

This study targets ALP above ULN but below 1.67 times ULN, rather than the higher ALP population in EPICS-III. Planned enrollment is 89 participants. The report contains a study design and eligibility record, but no treatment-effect estimates or observed safety results.

Source: [Veeva Systems EPICS-IV study page](https://ctv.veeva.com/study/study-of-saroglitazar-magnesium-for-pbc-patients-with-incomplete-response-or-intolerant-to-udca-ther); [EU Clinical Trials Register EudraCT 2022-001634-10](https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-001634-10/ES)

<a id="heading-3.1.3"></a>

#### 3.1.3 EPICS-V

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Long-term clinical-outcomes objective

> “time to the first occurrence of the defined clinical outcome events in participants with PBC”

Source: [ClinicalTrials.gov NCT07216235](https://clinicaltrials.gov/study/NCT07216235)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

No evidence found.

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Randomized phase 3b/4 study

> “Double Blind, Placebo Controlled”

Source: [Veeva Systems EPICS-V study page](https://ctv.veeva.com/study/long-term-study-to-evaluate-the-safety-and-efficacy-in-participants-with-primary-biliary-cholangitis)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Cirrhosis and biochemical eligibility

> “Has documented evidence of cirrhosis”
> “ALP >ULN and TB ≤5 × ULN”

Source: [Veeva Systems EPICS-V study page](https://ctv.veeva.com/study/long-term-study-to-evaluate-the-safety-and-efficacy-in-participants-with-primary-biliary-cholangitis)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Saroglitazar magnesium: oral morning dosing

> “1 mg, once daily”

Source: [Veeva Systems EPICS-V study page](https://ctv.veeva.com/study/long-term-study-to-evaluate-the-safety-and-efficacy-in-participants-with-primary-biliary-cholangitis)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Time to First Clinical Outcome Event as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Clinical-outcome observation period

> “baseline to 48 months”

Source: [ClinicalTrials.gov NCT07216235](https://clinicaltrials.gov/study/NCT07216235)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Planned enrollment

| Population | Estimated participants |
| --- | --- |
| Long-term randomized study | “386” |

Source: [Veeva Systems EPICS-V study page](https://ctv.veeva.com/study/long-term-study-to-evaluate-the-safety-and-efficacy-in-participants-with-primary-biliary-cholangitis)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

No evidence found.

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

The planned study evaluates clinical outcomes over 48 months in a population with cirrhosis. Estimated enrollment is 386 participants. The retrieved evidence does not yet establish an effect on clinical events, and its cirrhotic eligibility population differs from the biochemical-response populations of earlier trials.

Source: [ClinicalTrials.gov NCT07216235](https://clinicaltrials.gov/study/NCT07216235); [Veeva Systems EPICS-V study page](https://ctv.veeva.com/study/long-term-study-to-evaluate-the-safety-and-efficacy-in-participants-with-primary-biliary-cholangitis)

<a id="heading-3.1.4"></a>

#### 3.1.4 EPICS

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Phase II proof-of-concept study: NCT03112681

> “Effect of a 16-week Treatment Regimen of Saroglitazar Magnesium 2 mg and 4 mg on Alkaline Phosphatase (ALP) Levels”

Source: [ClinicalTrials.gov NCT03112681](https://clinicaltrials.gov/study/NCT03112681)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

No evidence found.

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Double-blind randomized proof-of-concept design

> “double-blind, phase II proof-of-concept trial”

Source: [Vuppalanchi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34487750/)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Prior UDCA response

> “UDCA) resistant or intolerant”

Source: [Vuppalanchi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34487750/)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Randomized daily treatment groups

| Treatment parameter | Saroglitazar 4 mg | Saroglitazar 2 mg | Placebo |
| --- | --- | --- | --- |
| Daily dose | “4 mg” | “2 mg” | “placebo” |
| Treatment duration | “16 weeks” | “16 weeks” | “16 weeks” |

Source: [Vuppalanchi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34487750/)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using ALP Reduction as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### ALP and bilirubin as prognostic markers

> “Combining levels of alkaline phosphatase and bilirubin increased the ability to predict patient survival times.”

Source: [Lammers et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25160979/)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Phase II proof-of-concept study: study population

> “37”

Source: [Vuppalanchi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34487750/)

<a id="topic-3.1.4.7.1-2"></a>

###### Randomized allocation

| Group | Participants |
| --- | --- |
| Saroglitazar 4 mg | “13” |
| Saroglitazar 2 mg | “14” |
| Placebo | “10” |

Source: [Vuppalanchi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34487750/)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Primary analysis population

> “modified ITT analysis”

Source: [Vuppalanchi et al. (2020)](https://assets.website-files.com/5f3d77cd56d46907a50fb8d9/5f9d9c2057efc43f55b78db7_2020%20TLMdX%20Late-breaking%20Abstracts-%20Oct%2030.pdf)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Study-drug discontinuations because of aminotransferase increases

| Group | Participants |
| --- | --- |
| All saroglitazar groups | “4” |
| Saroglitazar 4 mg | “3” |
| Saroglitazar 2 mg | “1” |

Source: [Vuppalanchi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34487750/)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

###### Baseline comparisons between treatment groups

> “not significantly different”

Source: [Vuppalanchi et al. (2020)](https://assets.website-files.com/5f3d77cd56d46907a50fb8d9/5f9d9c2057efc43f55b78db7_2020%20TLMdX%20Late-breaking%20Abstracts-%20Oct%2030.pdf)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Phase II proof-of-concept study: week 16 ALP endpoints

| Week 16 endpoint | Saroglitazar 4 mg | Saroglitazar 2 mg | Placebo |
| --- | --- | --- | --- |
| Mean percentage ALP reduction | “49%” | “51%” | “3%” |
| Least-squares mean ALP change, U/L | “-163.3” | “-155.8” | “-21.1” |

Source: [Vuppalanchi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34487750/)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.4.8.4-1"></a>

###### Week 16 PBC-40 itch domain

> “The mean change from baseline on the itch domain of the PBC-40 questionnaire at Week 16 was -1.52, -1.08 and -2.31, respectively, for saroglitazar 4 mg, saroglitazar 2 mg and placebo groups.”
> “Overall, no worsening of pruritus was observed on the itch domain of the PBC-40 questionnaire”
> “13 (35.1%) patients reported pruritus at baseline”

Source: [Vuppalanchi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34487750/)

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Participants with at least one treatment-emergent adverse event

| Outcome | Saroglitazar 4 mg | Saroglitazar 2 mg | Placebo |
| --- | --- | --- | --- |
| Participants, n (%) | “11 (84.6%)” | “12 (85.7%)” | “8 (80%)” |

Source: [Vuppalanchi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34487750/)

<a id="topic-3.1.4.8.5-2"></a>

###### Aminotransferase increases after treatment discontinuation

> “due to aminotransferase increases that promptly returned to baseline values after drug discontinuation.”

Source: [Vuppalanchi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34487750/)

<a id="topic-3.1.4.8.5-3"></a>

###### EPICS phase II study: conference publication

> “Liver tests returned to baseline after study drug discontinuation in 3 while one patient required immune suppression for suspected overlap syndrome.”

Source: [Vuppalanchi et al. (2020)](https://assets.website-files.com/5f3d77cd56d46907a50fb8d9/5f9d9c2057efc43f55b78db7_2020%20TLMdX%20Late-breaking%20Abstracts-%20Oct%2030.pdf)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

This 37-participant trial lasted 16 weeks and tested 2 mg and 4 mg, not the later 1 mg magnesium regimen. Four participants discontinued treatment because of aminotransferase increases. The conference report describes one participant requiring immune suppression for suspected overlap syndrome, whereas the journal abstract summarizes recovery after discontinuation. Neither report establishes a long-term clinical-outcome benefit.

Source: [Vuppalanchi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34487750/); [Vuppalanchi et al. (2020)](https://assets.website-files.com/5f3d77cd56d46907a50fb8d9/5f9d9c2057efc43f55b78db7_2020%20TLMdX%20Late-breaking%20Abstracts-%20Oct%2030.pdf); [ClinicalTrials.gov NCT05133336](https://clinicaltrials.gov/study/NCT05133336)

<a id="topic-3.1.4.9-2"></a>

###### Investigator-stated limitation on the pruritus finding

> “There were anecdotal reports of improvement in itching while on treatment with saroglitazar, but the current study does not provide any conclusive evidence, primarily because of the low prevalence of itching in study participants and the lack of additional measurements of itch severity.”

Source: [Vuppalanchi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34487750/)

<a id="heading-3.1.5"></a>

#### 3.1.5 Open-label single-arm study

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### ALP-response assessment

> “ALP”

Source: [Vuppalanchi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7997082/)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Study population: Mexico

> “Mexican”

Source: [Vuppalanchi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7997082/)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Open-label design

> “open-label”

Source: [Vuppalanchi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7997082/)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Prior treatment: ongoing UDCA

> “ongoing treatment with UDCA”

Source: [Vuppalanchi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7997082/)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Open-label, single-arm study: regimen

| Field | Quoted finding |
| --- | --- |
| Regimen | “4 mg for 16 weeks” |

Source: [Vuppalanchi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7997082/)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using ALP Reduction as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Prognostic association of ALP and bilirubin

> “Combining levels of alkaline phosphatase and bilirubin increased the ability to predict patient survival times.”

Source: [Lammers et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25160979/)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Open-label, single-arm study: enrollment

| Field | Quoted finding |
| --- | --- |
| Enrolled patients | “7” |

Source: [Vuppalanchi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7997082/)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Primary analysis population

> “modified intent-to-treat”

Source: [Vuppalanchi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7997082/)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### Open-label, single-arm study: termination

| Field | Quoted finding |
| --- | --- |
| Reason for study termination | “lack of enrollment” |

Source: [Vuppalanchi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7997082/)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

###### Open-label, single-arm study: baseline characteristics

| Field | Quoted finding |
| --- | --- |
| Sex | “all patients were female” |
| Mean age, years | “51.1 ± 10.0” |
| Mean baseline ALP, U/L | “230 ± 103” |

Source: [Vuppalanchi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7997082/)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Open-label, single-arm study: ALP response

| Field | Quoted finding |
| --- | --- |
| Mean ALP reduction at Week 16 | “48 ± 23%” |

Source: [Vuppalanchi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7997082/)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

No evidence found.

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

Only seven participants were enrolled, all female, and the study ended because of lack of enrollment. Its open-label, single-arm design cannot separate treatment effects from changes that would have occurred without saroglitazar. The 16-week biochemical assessment does not establish a transplantation or survival benefit.

Source: [Vuppalanchi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7997082/)

<a id="heading-3.1.6"></a>

#### 3.1.6 SARO.23.002

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

###### Extension objective

> “Safety and Efficacy”

Source: [Veeva Systems SARO.23.002 study page](https://ctv.veeva.com/study/open-label-extension-study-of-saroglitazar-magnesium-in-participants-with-primary-biliary-cholangiti)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

No evidence found.

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Open-label extension design

> “Single Group Assignment”

Source: [Veeva Systems SARO.23.002 study page](https://ctv.veeva.com/study/open-label-extension-study-of-saroglitazar-magnesium-in-participants-with-primary-biliary-cholangiti)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

###### Eligibility after the parent trial

> “Participated and completed SARO.21.001, the double-blind treatment phase study”

Source: [Veeva Systems SARO.23.002 study page](https://ctv.veeva.com/study/open-label-extension-study-of-saroglitazar-magnesium-in-participants-with-primary-biliary-cholangiti)

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

###### Open-label extension: dosage and duration

> “Saroglitazar Magnesium 1 mg tablet orally administered once daily”
> “24 months”

Source: [ClinicalTrials.gov NCT06427395](https://clinicaltrials.gov/study/NCT06427395)

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Safety During Extended Treatment as the Primary Endpoint

Not applicable.

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Registry-reported enrollment

| Population | Participants |
| --- | --- |
| Open-label extension | “102” |

Source: [Veeva Systems SARO.23.002 study page](https://ctv.veeva.com/study/open-label-extension-study-of-saroglitazar-magnesium-in-participants-with-primary-biliary-cholangiti)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

No evidence found.

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary

Eligibility requires completion of the parent double-blind trial. This selects participants able to complete earlier treatment and does not recreate a randomized untreated comparator. The registry reports 102 participants, but the report contains no extension results.

Source: [Veeva Systems SARO.23.002 study page](https://ctv.veeva.com/study/open-label-extension-study-of-saroglitazar-magnesium-in-participants-with-primary-biliary-cholangiti)

<a id="heading-3.1.7"></a>

#### 3.1.7 RESPONSE

<a id="heading-3.1.7.1"></a>

##### 3.1.7.1 Objective

<a id="topic-3.1.7.1-1"></a>

###### Biochemical-response objective

> “biochemical response at Month 12”

Source: [LIVDELZI prescribing information (2026)](https://www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.pdf)

<a id="heading-3.1.7.2"></a>

##### 3.1.7.2 Location and Study Date

<a id="topic-3.1.7.2-1"></a>

###### U.S. participation

| Population characteristic | Reported value |
| --- | --- |
| Participants enrolled in the United States | “Thirty-two percent” |

Source: [LIVDELZI prescribing information (2026)](https://www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.pdf)

<a id="heading-3.1.7.3"></a>

##### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

###### Randomized, double-blind trial duration

> “12-month”

Source: [LIVDELZI prescribing information (2026)](https://www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.pdf)

<a id="heading-3.1.7.4"></a>

##### 3.1.7.4 Eligibility Criteria

<a id="topic-3.1.7.4-1"></a>

###### Biochemical eligibility

| Criterion | Quoted threshold |
| --- | --- |
| ALP: at least this multiple of ULN | “1.67” |
| Total bilirubin: at most this multiple of ULN | “2” |

Source: [LIVDELZI prescribing information (2026)](https://www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.pdf)

<a id="heading-3.1.7.5"></a>

##### 3.1.7.5 Treatment

<a id="topic-3.1.7.5-1"></a>

###### Daily treatment allocation

| Treatment | Dose |
| --- | --- |
| Seladelpar | “10 mg” |
| Comparator | “placebo” |

Source: [LIVDELZI prescribing information (2026)](https://www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.pdf)

<a id="heading-3.1.7.6"></a>

##### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

###### 3.1.7.6.1 Rationale for Using ALP and Bilirubin Biochemical Response as the Primary Endpoint

<a id="topic-3.1.7.6.1-1"></a>

###### ALP and bilirubin as prognostic markers

> “Combining levels of alkaline phosphatase and bilirubin increased the ability to predict patient survival times.”

Source: [Lammers et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25160979/)

<a id="heading-3.1.7.7"></a>

##### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

###### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

###### Randomized population

| Treatment | Participants |
| --- | --- |
| Seladelpar | “128” |
| Placebo | “65” |

Source: [LIVDELZI prescribing information (2026)](https://www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.pdf)

<a id="heading-3.1.7.7.2"></a>

###### 3.1.7.7.2 Description of Analysis Sets

<a id="topic-3.1.7.7.2-1"></a>

###### Early treatment discontinuation or missing month 12 data

> “non-responders”

Source: [LIVDELZI prescribing information (2026)](https://www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.pdf)

<a id="topic-3.1.7.7.2-2"></a>

###### Biochemical-response hypothesis test

> “Cochran–Mantel–Haenszel”

Source: [LIVDELZI prescribing information (2026)](https://www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.pdf)

<a id="heading-3.1.7.8"></a>

##### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

###### 3.1.7.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.7.8.2"></a>

###### 3.1.7.8.2 Baseline Characteristics

<a id="topic-3.1.7.8.2-1"></a>

###### Baseline population

| Characteristic | Reported value |
| --- | --- |
| Mean age, years | “57” |
| Female participants | “95%” |
| Mean ALP, U/L | “314” |

Source: [LIVDELZI prescribing information (2026)](https://www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.pdf)

<a id="heading-3.1.7.8.3"></a>

###### 3.1.7.8.3 Efficacy Results

<a id="topic-3.1.7.8.3-1"></a>

###### Month 12 biochemical results

| Outcome | Seladelpar | Placebo |
| --- | --- | --- |
| Biochemical response, n (%) | “79 (62)” | “13 (20)” |
| ALP normalization, n (%) | “32 (25)” | “0 (0)” |

Source: [LIVDELZI prescribing information (2026)](https://www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.pdf)

<a id="topic-3.1.7.8.3-2"></a>

###### Month 12 biochemical response and alkaline phosphatase normalization: between-group differences

> “A greater percentage of the patients in the seladelpar group than in the placebo group had a biochemical response (61.7% vs. 20.0%; difference, 41.7 percentage points; 95% confidence interval [CI], 27.7 to 53.4, P<0.001).”
> “Normalization of the alkaline phosphatase level also occurred in a greater percentage of patients who received seladelpar than of those who received placebo (25.0% vs. 0%; difference, 25.0 percentage points; 95% CI, 18.3 to 33.2, P<0.001).”
> “Of the 193 patients who underwent randomization and treatment, 93.8% received ursodeoxycholic acid as standard-of-care background therapy.”

Source: [Hirschfield et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38381664/)

<a id="heading-3.1.7.8.4"></a>

###### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.7.8.4-1"></a>

###### Month 6 pruritus: baseline average score at least 4

| Outcome | Seladelpar | Placebo |
| --- | --- | --- |
| Analysis participants | “49” | “23” |
| Mean change in score, standard error | “-3.2 (0.3)” | “-1.7 (0.4)” |

Source: [LIVDELZI prescribing information (2026)](https://www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.pdf)

<a id="topic-3.1.7.8.4-2"></a>

###### Month 6 pruritus: least-squares mean difference against placebo

> “Seladelpar resulted in a greater reduction in the score on the pruritus numerical rating scale than placebo (least-squares mean change from baseline, −3.2 vs. −1.7; least-squares mean difference, −1.5; 95% CI, −2.5 to −0.5, P = 0.005).”

Source: [Hirschfield et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38381664/)

<a id="heading-3.1.7.8.5"></a>

###### 3.1.7.8.5 Safety Results

<a id="topic-3.1.7.8.5-1"></a>

###### Fractures during the trial

| Outcome | Seladelpar | Placebo |
| --- | --- | --- |
| Participants with fractures | “4%” | “no” |

Source: [LIVDELZI prescribing information (2026)](https://www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.pdf)

<a id="topic-3.1.7.8.5-2"></a>

###### Overall and serious adverse events

> “Adverse events were reported in 86.7% of the patients in the seladelpar group and in 84.6% in the placebo group, and serious adverse events in 7.0% and 6.2%, respectively.”
> “The incidence and severity of adverse events were similar in the two groups.”

Source: [Hirschfield et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38381664/)

<a id="heading-3.1.7.9"></a>

##### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

###### Summary

This is comparator evidence, not a randomized comparison against saroglitazar. The primary endpoint was biochemical response after 12 months, and the pruritus analysis concerned a subgroup with baseline scores of at least 4. The prescribing information does not establish improved survival or prevention of liver decompensation.

Source: [LIVDELZI prescribing information (2026)](https://www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.pdf)

<a id="heading-3.1.8"></a>

#### 3.1.8 ELATIVE

<a id="heading-3.1.8.1"></a>

##### 3.1.8.1 Objective

<a id="topic-3.1.8.1-1"></a>

###### Biochemical-response objective

> “biochemical response at Week 52”

Source: [FDA IQIRVO prescribing information](https://www.fda.gov/media/180873/download)

<a id="heading-3.1.8.2"></a>

##### 3.1.8.2 Location and Study Date

No evidence found.

<a id="heading-3.1.8.3"></a>

##### 3.1.8.3 Study Design

<a id="topic-3.1.8.3-1"></a>

###### Randomized multicenter design

> “multi-center, randomized, double-blind, placebo-controlled study”

Source: [FDA IQIRVO prescribing information](https://www.fda.gov/media/180873/download)

<a id="heading-3.1.8.4"></a>

##### 3.1.8.4 Eligibility Criteria

<a id="topic-3.1.8.4-1"></a>

###### Biochemical eligibility

| Criterion | Quoted threshold |
| --- | --- |
| ALP: at least this multiple of ULN | “1.67” |
| Total bilirubin: at most this multiple of ULN | “2” |

Source: [FDA IQIRVO prescribing information](https://www.fda.gov/media/180873/download)

<a id="heading-3.1.8.5"></a>

##### 3.1.8.5 Treatment

<a id="topic-3.1.8.5-1"></a>

###### Daily treatment allocation

| Treatment | Dose |
| --- | --- |
| Elafibranor | “80 mg” |
| Comparator | “placebo” |

Source: [FDA IQIRVO prescribing information](https://www.fda.gov/media/180873/download)

<a id="heading-3.1.8.6"></a>

##### 3.1.8.6 Study Outcomes

<a id="heading-3.1.8.6.1"></a>

###### 3.1.8.6.1 Rationale for Using ALP and Bilirubin Biochemical Response as the Primary Endpoint

<a id="topic-3.1.8.6.1-1"></a>

###### ALP and bilirubin as prognostic markers

> “Combining levels of alkaline phosphatase and bilirubin increased the ability to predict patient survival times.”

Source: [Lammers et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25160979/)

<a id="heading-3.1.8.7"></a>

##### 3.1.8.7 Statistical Analysis Description

<a id="heading-3.1.8.7.1"></a>

###### 3.1.8.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.8.7.1-1"></a>

###### Randomized population

| Treatment | Participants |
| --- | --- |
| Elafibranor | “108” |
| Placebo | “53” |

Source: [FDA IQIRVO prescribing information](https://www.fda.gov/media/180873/download)

<a id="heading-3.1.8.7.2"></a>

###### 3.1.8.7.2 Description of Analysis Sets

<a id="topic-3.1.8.7.2-1"></a>

###### Early treatment cessation or rescue treatment before week 52

> “non-responders”

Source: [FDA IQIRVO prescribing information](https://www.fda.gov/media/180873/download)

<a id="topic-3.1.8.7.2-2"></a>

###### Primary response analysis

> “exact Cochran–Mantel–Haenszel (CMH) test”

Source: [FDA IQIRVO prescribing information](https://www.fda.gov/media/180873/download)

<a id="heading-3.1.8.8"></a>

##### 3.1.8.8 Results

<a id="heading-3.1.8.8.1"></a>

###### 3.1.8.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.8.8.2"></a>

###### 3.1.8.8.2 Baseline Characteristics

<a id="topic-3.1.8.8.2-1"></a>

###### Baseline population

| Characteristic | Reported value |
| --- | --- |
| Mean age, years | “57” |
| Female participants | “96%” |
| Mean ALP, U/L | “321.9” |

Source: [FDA IQIRVO prescribing information](https://www.fda.gov/media/180873/download)

<a id="heading-3.1.8.8.3"></a>

###### 3.1.8.8.3 Efficacy Results

<a id="topic-3.1.8.8.3-1"></a>

###### Week 52 biochemical results

| Outcome | Elafibranor | Placebo |
| --- | --- | --- |
| Biochemical response, n (%) | “55 (51)” | “2 (4)” |
| ALP normalization, n (%) | “16 (15)” | “0 (0)” |

Source: [FDA IQIRVO prescribing information](https://www.fda.gov/media/180873/download)

<a id="topic-3.1.8.8.3-2"></a>

###### Week 52 biochemical response and alkaline phosphatase normalization: between-group differences

> “A biochemical response (the primary end point) was observed in 51% of the patients (55 of 108) who received elafibranor and in 4% (2 of 53) who received placebo, for a difference of 47 percentage points (95% confidence interval [CI], 32 to 57; P<0.001).”
> “The alkaline phosphatase level normalized in 15% of the patients in the elafibranor group and in none of the patients in the placebo group at week 52 (difference, 15 percentage points; 95% CI, 6 to 23; P=0.002).”
> “Treatment with elafibranor resulted in significantly greater improvements in relevant biochemical indicators of cholestasis than placebo.”

Source: [Kowdley et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37962077/)

<a id="heading-3.1.8.8.4"></a>

###### 3.1.8.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.8.8.4-1"></a>

###### Week 52 pruritus: moderate-to-severe pruritus subgroup

> “Among patients who had moderate-to-severe pruritus (44 patients in the elafibranor group and 22 in the placebo group), the least-squares mean change from baseline through week 52 on the WI-NRS did not differ significantly between the groups (−1.93 vs. −1.15; difference, −0.78; 95% CI, −1.99 to 0.42; P=0.20).”

Source: [Kowdley et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37962077/)

<a id="heading-3.1.8.8.5"></a>

###### 3.1.8.8.5 Safety Results

<a id="topic-3.1.8.8.5-1"></a>

###### Selected adverse reactions during the double-blind period

| Adverse reaction | Elafibranor | Placebo |
| --- | --- | --- |
| Diarrhea, % (n) | “11% (12)” | “9% (5)” |
| Muscle pain, % (n) | “7% (8)” | “2% (1)” |
| Fracture, % (n) | “6% (7)” | “0” |

Source: [FDA IQIRVO prescribing information](https://www.fda.gov/media/180873/download)

<a id="topic-3.1.8.8.5-2"></a>

###### Adverse events more frequent with elafibranor than placebo

> “Adverse events that occurred more frequently with elafibranor than with placebo included abdominal pain, diarrhea, nausea, and vomiting.”

Source: [Kowdley et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37962077/)

<a id="heading-3.1.8.9"></a>

##### 3.1.8.9 Study Limitations

<a id="topic-3.1.8.9-1"></a>

###### Summary

This comparator trial does not provide a head-to-head estimate against saroglitazar. Its primary endpoint was biochemical response at 52 weeks. The population was 96% female, and eligibility excluded decompensated cirrhosis, limiting extrapolation to that population.

Source: [FDA IQIRVO prescribing information](https://www.fda.gov/media/180873/download)

<a id="heading-3.1.9"></a>

#### 3.1.9 BEZURSO

<a id="heading-3.1.9.1"></a>

##### 3.1.9.1 Objective

<a id="topic-3.1.9.1-1"></a>

###### Primary objective

> “complete biochemical response”

Source: [Corpechot et al. (2018)](https://scholars.mssm.edu/en/publications/a-placebo-controlled-trial-of-bezafibrate-in-primary-biliary-chol/)

<a id="heading-3.1.9.2"></a>

##### 3.1.9.2 Location and Study Date

No evidence found.

<a id="heading-3.1.9.3"></a>

##### 3.1.9.3 Study Design

<a id="topic-3.1.9.3-1"></a>

###### Double-blind, placebo-controlled phase 3 design: duration

> “24-month”

Source: [Corpechot et al. (2018)](https://scholars.mssm.edu/en/publications/a-placebo-controlled-trial-of-bezafibrate-in-primary-biliary-chol/)

<a id="heading-3.1.9.4"></a>

##### 3.1.9.4 Eligibility Criteria

<a id="topic-3.1.9.4-1"></a>

###### Inadequate UDCA response criterion

> “Paris 2 criteria”

Source: [Corpechot et al. (2018)](https://scholars.mssm.edu/en/publications/a-placebo-controlled-trial-of-bezafibrate-in-primary-biliary-chol/)

<a id="heading-3.1.9.5"></a>

##### 3.1.9.5 Treatment

<a id="topic-3.1.9.5-1"></a>

###### Bezafibrate daily dose in addition to UDCA

> “400 mg”

Source: [Corpechot et al. (2018)](https://scholars.mssm.edu/en/publications/a-placebo-controlled-trial-of-bezafibrate-in-primary-biliary-chol/)

<a id="heading-3.1.9.6"></a>

##### 3.1.9.6 Study Outcomes

<a id="heading-3.1.9.6.1"></a>

###### 3.1.9.6.1 Rationale for Using Complete Biochemical Response as the Primary Endpoint

<a id="topic-3.1.9.6.1-1"></a>

###### Complete biochemical-response definition

> “normal levels of total bilirubin, alkaline phosphatase, aminotransferases, and albumin”

Source: [Corpechot et al. (2018)](https://scholars.mssm.edu/en/publications/a-placebo-controlled-trial-of-bezafibrate-in-primary-biliary-chol/)

<a id="topic-3.1.9.6.1-2"></a>

###### Additional primary-response criterion

> “a normal prothrombin index”

Source: [Corpechot et al. (2018)](https://scholars.mssm.edu/en/publications/a-placebo-controlled-trial-of-bezafibrate-in-primary-biliary-chol/)

<a id="topic-3.1.9.6.1-3"></a>

###### Biochemical-marker relevance

> “Combining levels of alkaline phosphatase and bilirubin increased the ability to predict patient survival times.”

Source: [Lammers et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25160979/)

<a id="heading-3.1.9.7"></a>

##### 3.1.9.7 Statistical Analysis Description

<a id="heading-3.1.9.7.1"></a>

###### 3.1.9.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.9.7.1-1"></a>

###### Randomized population

| Treatment | Participants |
| --- | --- |
| Bezafibrate | “50” |
| Placebo | “50” |

Source: [Corpechot et al. (2018)](https://scholars.mssm.edu/en/publications/a-placebo-controlled-trial-of-bezafibrate-in-primary-biliary-chol/)

<a id="heading-3.1.9.7.2"></a>

###### 3.1.9.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.9.8"></a>

##### 3.1.9.8 Results

<a id="heading-3.1.9.8.1"></a>

###### 3.1.9.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.9.8.2"></a>

###### 3.1.9.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.9.8.3"></a>

###### 3.1.9.8.3 Efficacy Results

<a id="topic-3.1.9.8.3-1"></a>

###### Month 24 biochemical results

| Outcome | Bezafibrate | Placebo |
| --- | --- | --- |
| Complete biochemical response | “31%” | “0%” |
| ALP normalization | “67%” | “2%” |

Source: [Corpechot et al. (2018)](https://scholars.mssm.edu/en/publications/a-placebo-controlled-trial-of-bezafibrate-in-primary-biliary-chol/)

<a id="heading-3.1.9.8.4"></a>

###### 3.1.9.8.4 Health-related Quality of Life and Patient-reported Outcomes

Additional sources: [Corpechot et al. (2018)](https://scholars.mssm.edu/en/publications/a-placebo-controlled-trial-of-bezafibrate-in-primary-biliary-chol/)

<a id="heading-3.1.9.8.5"></a>

###### 3.1.9.8.5 Safety Results

<a id="topic-3.1.9.8.5-1"></a>

###### Selected safety outcomes

| Outcome | Bezafibrate | Placebo |
| --- | --- | --- |
| Myalgia | “20%” | “10%” |
| Creatinine change from baseline: increase or decrease, respectively | “5%” | “3%” |

Source: [Corpechot et al. (2018)](https://scholars.mssm.edu/en/publications/a-placebo-controlled-trial-of-bezafibrate-in-primary-biliary-chol/)

<a id="heading-3.1.9.9"></a>

##### 3.1.9.9 Study Limitations

<a id="topic-3.1.9.9-1"></a>

###### Summary

This 100-participant comparator trial lasted 24 months and evaluated bezafibrate added to UDCA, not saroglitazar. Its complete biochemical-response definition differs from the EPICS-III composite, so the response percentages are not interchangeable across studies.

Source: [Corpechot et al. (2018)](https://scholars.mssm.edu/en/publications/a-placebo-controlled-trial-of-bezafibrate-in-primary-biliary-chol/); [Zydus Therapeutics (2025)](https://www.prnewswire.com/news-releases/zydus-therapeutics-reports-positive-topline-results-from-epics-iii-phase-2b3-trial-of-saroglitazar-magnesium-in-patients-with-primary-biliary-cholangitis-302542014.html)

<a id="heading-3.1.10"></a>

#### 3.1.10 ZYH1 first-in-human study

<a id="heading-3.1.10.1"></a>

##### 3.1.10.1 Objective

<a id="topic-3.1.10.1-1"></a>

###### Pharmacokinetics, safety, and tolerability objective

> “healthy human subjects”

Source: [Jani et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3824340/)

<a id="heading-3.1.10.2"></a>

##### 3.1.10.2 Location and Study Date

<a id="topic-3.1.10.2-1"></a>

###### Study conduct dates

> “16 June 2005 to 29 November 2005”

Source: [Jani et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3824340/)

<a id="heading-3.1.10.3"></a>

##### 3.1.10.3 Study Design

<a id="topic-3.1.10.3-1"></a>

###### Single-center randomized design

> “randomized, double-blind, placebo-controlled, single-centre”

Source: [Jani et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3824340/)

<a id="heading-3.1.10.4"></a>

##### 3.1.10.4 Eligibility Criteria

<a id="topic-3.1.10.4-1"></a>

###### Healthy-volunteer age range

| Criterion | Age, years |
| --- | --- |
| Minimum | “18” |
| Maximum | “45” |

Source: [Jani et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3824340/)

<a id="heading-3.1.10.5"></a>

##### 3.1.10.5 Treatment

<a id="topic-3.1.10.5-1"></a>

###### Single-dose range and food/sex substudy

| Study component | Dose |
| --- | --- |
| Lowest ascending dose, mg | “0.125” |
| Highest ascending dose, mg | “128” |
| Food/sex substudy dose, mg | “1” |

Source: [Jani et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3824340/)

<a id="heading-3.1.10.6"></a>

##### 3.1.10.6 Study Outcomes

<a id="heading-3.1.10.6.1"></a>

###### 3.1.10.6.1 Rationale for Using Pharmacokinetic Parameters as the Primary Endpoint

Not applicable.

<a id="heading-3.1.10.7"></a>

##### 3.1.10.7 Statistical Analysis Description

<a id="heading-3.1.10.7.1"></a>

###### 3.1.10.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.10.7.1-1"></a>

###### Enrollment accounting

| Population | Participants |
| --- | --- |
| Unique participants overall | “96” |
| Part I: healthy men | “88” |
| Part II: men and women | “16” |

Source: [Jani et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3824340/)

<a id="heading-3.1.10.7.2"></a>

###### 3.1.10.7.2 Description of Analysis Sets

<a id="topic-3.1.10.7.2-1"></a>

###### Pharmacokinetic analysis

> “non-compartmental”

Source: [Jani et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3824340/)

<a id="heading-3.1.10.8"></a>

##### 3.1.10.8 Results

<a id="heading-3.1.10.8.1"></a>

###### 3.1.10.8.1 Participant Disposition

<a id="topic-3.1.10.8.1-1"></a>

###### Part I completion

| Population | Participants |
| --- | --- |
| Completed Part I | “87” |

Source: [Jani et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3824340/)

<a id="heading-3.1.10.8.2"></a>

###### 3.1.10.8.2 Baseline Characteristics

<a id="topic-3.1.10.8.2-1"></a>

###### Part II sex distribution

| Sex | Participants |
| --- | --- |
| Male | “8” |
| Female | “8” |

Source: [Jani et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3824340/)

<a id="heading-3.1.10.8.3"></a>

###### 3.1.10.8.3 Efficacy Results

<a id="topic-3.1.10.8.3-1"></a>

###### Renal elimination

> “Saroglitazar was not eliminated via the renal route.”

Source: [Jani et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3824340/)

<a id="topic-3.1.10.8.3-2"></a>

###### Dosage-interval interpretation

> “The pharmacokinetics of saroglitazar support a once daily dosage schedule.”

Source: [Jani et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3824340/)

<a id="heading-3.1.10.8.4"></a>

###### 3.1.10.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.10.8.5"></a>

###### 3.1.10.8.5 Safety Results

<a id="topic-3.1.10.8.5-1"></a>

###### Serious adverse events

> “No serious adverse events were reported.”

Source: [Jani et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3824340/)

<a id="heading-3.1.10.9"></a>

##### 3.1.10.9 Study Limitations

<a id="topic-3.1.10.9-1"></a>

###### Summary

This single-dose study enrolled healthy volunteers, not participants with PBC. Its 96 unique participants included eight men who participated in both parts, so the part-specific enrollments should not be added without accounting for overlap. It does not establish efficacy or repeated-dose safety in PBC.

Source: [Jani et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3824340/)

<a id="heading-3.1.11"></a>

#### 3.1.11 Saroglitazar magnesium food-effect study

<a id="heading-3.1.11.1"></a>

##### 3.1.11.1 Objective

<a id="topic-3.1.11.1-1"></a>

###### Food-effect comparison

> “fed relative to fasting conditions”

Source: [Patel et al. (2018a)](https://pubmed.ncbi.nlm.nih.gov/29022212/)

<a id="heading-3.1.11.2"></a>

##### 3.1.11.2 Location and Study Date

No evidence found.

<a id="heading-3.1.11.3"></a>

##### 3.1.11.3 Study Design

<a id="topic-3.1.11.3-1"></a>

###### Randomized crossover design

> “single-dose, open-label, randomized”

Source: [Patel et al. (2018a)](https://pubmed.ncbi.nlm.nih.gov/29022212/)

<a id="heading-3.1.11.4"></a>

##### 3.1.11.4 Eligibility Criteria

<a id="topic-3.1.11.4-1"></a>

###### Healthy-volunteer population

> “healthy subjects”

Source: [Patel et al. (2018a)](https://pubmed.ncbi.nlm.nih.gov/29022212/)

<a id="heading-3.1.11.5"></a>

##### 3.1.11.5 Treatment

<a id="topic-3.1.11.5-1"></a>

###### Single-dose tablet strength

> “4-mg tablet”

Source: [Patel et al. (2018a)](https://pubmed.ncbi.nlm.nih.gov/29022212/)

<a id="heading-3.1.11.6"></a>

##### 3.1.11.6 Study Outcomes

<a id="heading-3.1.11.6.1"></a>

###### 3.1.11.6.1 Rationale for Using Pharmacokinetic Parameters as the Primary Endpoint

Not applicable.

<a id="heading-3.1.11.7"></a>

##### 3.1.11.7 Statistical Analysis Description

<a id="heading-3.1.11.7.1"></a>

###### 3.1.11.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.11.7.1-1"></a>

###### Enrollment and analyzed population

| Population | Participants |
| --- | --- |
| Enrolled | “54” |
| Completed and analyzed | “50” |

Source: [Patel et al. (2018a)](https://pubmed.ncbi.nlm.nih.gov/29022212/)

<a id="heading-3.1.11.7.2"></a>

###### 3.1.11.7.2 Description of Analysis Sets

<a id="topic-3.1.11.7.2-1"></a>

###### Pharmacokinetic analysis

> “standard non-compartmental approach”

Source: [Patel et al. (2018a)](https://pubmed.ncbi.nlm.nih.gov/29022212/)

<a id="heading-3.1.11.8"></a>

##### 3.1.11.8 Results

<a id="heading-3.1.11.8.1"></a>

###### 3.1.11.8.1 Participant Disposition

<a id="topic-3.1.11.8.1-1"></a>

###### Study completion

| Disposition | Participants |
| --- | --- |
| Completed | “50” |

Source: [Patel et al. (2018a)](https://pubmed.ncbi.nlm.nih.gov/29022212/)

<a id="heading-3.1.11.8.2"></a>

###### 3.1.11.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.11.8.3"></a>

###### 3.1.11.8.3 Efficacy Results

<a id="topic-3.1.11.8.3-1"></a>

###### Food effect: healthy volunteers, 4-mg tablet

> “food reduced Cmax (maximum concentration) of saroglitazar by 30%”
> “there is no impact of food on the extent of absorption of saroglitazar.”

Source: [Patel et al. (2018a)](https://pubmed.ncbi.nlm.nih.gov/29022212/)

<a id="heading-3.1.11.8.4"></a>

###### 3.1.11.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.11.8.5"></a>

###### 3.1.11.8.5 Safety Results

<a id="topic-3.1.11.8.5-1"></a>

###### Reported adverse-event severity

> “mild in nature”

Source: [Patel et al. (2018a)](https://pubmed.ncbi.nlm.nih.gov/29022212/)

<a id="heading-3.1.11.9"></a>

##### 3.1.11.9 Study Limitations

<a id="topic-3.1.11.9-1"></a>

###### Summary

The study evaluated a single 4 mg tablet in healthy volunteers under fed and fasting conditions. Fifty of 54 enrolled participants completed and were analyzed. These results do not directly establish food effects after repeated 1 mg dosing in PBC.

Source: [Patel et al. (2018a)](https://pubmed.ncbi.nlm.nih.gov/29022212/)

<a id="heading-3.1.12"></a>

#### 3.1.12 SARO.19.003 Part A

<a id="heading-3.1.12.1"></a>

##### 3.1.12.1 Objective

<a id="topic-3.1.12.1-1"></a>

###### Hepatic-impairment pharmacokinetic objective

> “pharmacokinetics”

Source: [Lawitz et al. (2023)](https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.1339)

<a id="heading-3.1.12.2"></a>

##### 3.1.12.2 Location and Study Date

No evidence found.

<a id="heading-3.1.12.3"></a>

##### 3.1.12.3 Study Design

<a id="topic-3.1.12.3-1"></a>

###### Single-dose parallel-group study

> “open-label”

Source: [Lawitz et al. (2023)](https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.1339)

<a id="heading-3.1.12.4"></a>

##### 3.1.12.4 Eligibility Criteria

<a id="topic-3.1.12.4-1"></a>

###### Hepatic-function comparison

> “hepatic impairment”

Source: [Lawitz et al. (2023)](https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.1339)

<a id="heading-3.1.12.5"></a>

##### 3.1.12.5 Treatment

<a id="topic-3.1.12.5-1"></a>

###### Single-dose hepatic-impairment cohorts

| Regimen | Dose |
| --- | --- |
| Oral saroglitazar | “4-mg” |

Source: [Lawitz et al. (2023)](https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.1339)

<a id="heading-3.1.12.6"></a>

##### 3.1.12.6 Study Outcomes

<a id="heading-3.1.12.6.1"></a>

###### 3.1.12.6.1 Rationale for Using Pharmacokinetic Parameters as the Primary Endpoint

Not applicable.

<a id="heading-3.1.12.7"></a>

##### 3.1.12.7 Statistical Analysis Description

<a id="heading-3.1.12.7.1"></a>

###### 3.1.12.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.12.7.1-1"></a>

###### Published hepatic-impairment cohorts

| Population | Participants |
| --- | --- |
| Hepatic impairment | “Thirty-two” |
| Normal hepatic function | “23” |

Source: [Lawitz et al. (2023)](https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.1339)

<a id="heading-3.1.12.7.2"></a>

###### 3.1.12.7.2 Description of Analysis Sets

<a id="topic-3.1.12.7.2-1"></a>

###### Pharmacokinetic analysis

> “non-compartmental”

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="heading-3.1.12.8"></a>

##### 3.1.12.8 Results

<a id="heading-3.1.12.8.1"></a>

###### 3.1.12.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.12.8.2"></a>

###### 3.1.12.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.12.8.3"></a>

###### 3.1.12.8.3 Efficacy Results

<a id="topic-3.1.12.8.3-1"></a>

###### Hepatic impairment: single-dose study

| Population or parameter | Quoted finding |
| --- | --- |
| Mild and moderate hepatic impairment | “did not significantly affect the PK of saroglitazar” |
| Severe hepatic impairment: exposure | “increased 3-fold” |
| Severe hepatic impairment: clearance | “61% lower” |
| Severe hepatic impairment: authors’ qualification | “may require close monitoring or dose adjustments” |

Source: [Lawitz et al. (2023)](https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.1339)

<a id="topic-3.1.12.8.3-2"></a>

###### Non-cirrhotic cholestatic liver disease: comparison with controls

> “comparable to matched controls”

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="heading-3.1.12.8.4"></a>

###### 3.1.12.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.12.8.5"></a>

###### 3.1.12.8.5 Safety Results

<a id="topic-3.1.12.8.5-1"></a>

###### Single-dose tolerability

> “well tolerated”

Source: [Lawitz et al. (2023)](https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.1339)

<a id="heading-3.1.12.9"></a>

##### 3.1.12.9 Study Limitations

<a id="topic-3.1.12.9-1"></a>

###### Summary

Single-dose pharmacokinetics do not establish repeated-dose safety or clinical efficacy. The 32 participants with hepatic impairment and 23 controls describe the published hepatic-impairment cohorts, not every cohort subsequently reported under this protocol. Severe impairment increased exposure, limiting extrapolation from mild or moderate impairment.

Source: [Lawitz et al. (2023)](https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.1339); [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="heading-3.1.13"></a>

#### 3.1.13 SARO.19.003 Part B

<a id="heading-3.1.13.1"></a>

##### 3.1.13.1 Objective

<a id="topic-3.1.13.1-1"></a>

###### Pharmacokinetic and pharmacodynamic assessment

> “pharmacodynamics”

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="heading-3.1.13.2"></a>

##### 3.1.13.2 Location and Study Date

<a id="topic-3.1.13.2-1"></a>

###### Study center

> “Indiana University”

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="heading-3.1.13.3"></a>

##### 3.1.13.3 Study Design

<a id="topic-3.1.13.3-1"></a>

###### Open-label multiple-dose study

> “open-label”

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="heading-3.1.13.4"></a>

##### 3.1.13.4 Eligibility Criteria

<a id="topic-3.1.13.4-1"></a>

###### PBC-cirrhosis population

> “mild or moderate HI”

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="heading-3.1.13.5"></a>

##### 3.1.13.5 Treatment

<a id="topic-3.1.13.5-1"></a>

###### Daily oral treatment

| Regimen characteristic | Reported value |
| --- | --- |
| Dose options, mg | “1 or 2” |
| Treatment duration, weeks | “4” |

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="heading-3.1.13.6"></a>

##### 3.1.13.6 Study Outcomes

<a id="heading-3.1.13.6.1"></a>

###### 3.1.13.6.1 Rationale for Using Pharmacokinetic Parameters as the Primary Endpoint

Not applicable.

<a id="heading-3.1.13.7"></a>

##### 3.1.13.7 Statistical Analysis Description

<a id="heading-3.1.13.7.1"></a>

###### 3.1.13.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.13.7.1-1"></a>

###### Enrollment including replacement

| Population | Participants |
| --- | --- |
| Enrolled | “19” |

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="heading-3.1.13.7.2"></a>

###### 3.1.13.7.2 Description of Analysis Sets

<a id="topic-3.1.13.7.2-1"></a>

###### Pharmacokinetic analysis

> “non-compartmental”

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="heading-3.1.13.8"></a>

##### 3.1.13.8 Results

<a id="heading-3.1.13.8.1"></a>

###### 3.1.13.8.1 Participant Disposition

<a id="topic-3.1.13.8.1-1"></a>

###### Replacement after withdrawal

> “replaced”

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="heading-3.1.13.8.2"></a>

###### 3.1.13.8.2 Baseline Characteristics

<a id="topic-3.1.13.8.2-1"></a>

###### Baseline sex distribution

| Sex | Participants |
| --- | --- |
| Male | “three” |
| Female | “16” |

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="heading-3.1.13.8.3"></a>

###### 3.1.13.8.3 Efficacy Results

<a id="topic-3.1.13.8.3-1"></a>

###### Moderate hepatic impairment: exposure and clearance

> “In moderate HI, exposure was significantly increased by 50.4–85% on days 1 and 28, with 34–46% lower clearance”

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="topic-3.1.13.8.3-2"></a>

###### ALP reduction after four weeks in participants with abnormal baseline ALP

| Outcome | Reported reduction |
| --- | --- |
| ALP reduction | “17–40%” |

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="heading-3.1.13.8.4"></a>

###### 3.1.13.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.13.8.5"></a>

###### 3.1.13.8.5 Safety Results

<a id="topic-3.1.13.8.5-1"></a>

###### Serious event in a participant receiving 2 mg

> “septic shock”

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="heading-3.1.13.9"></a>

##### 3.1.13.9 Study Limitations

<a id="topic-3.1.13.9-1"></a>

###### Summary

The study was open-label and lasted four weeks. It characterizes short-term pharmacokinetics rather than comparative clinical efficacy. Increased exposure in moderate hepatic impairment and the small cohort restrict extrapolation to longer treatment or broader cirrhotic populations.

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="heading-3.1.14"></a>

#### 3.1.14 SARO.19.004

<a id="heading-3.1.14.1"></a>

##### 3.1.14.1 Objective

<a id="topic-3.1.14.1-1"></a>

###### Renal-impairment pharmacokinetic objective

> “severe RI”

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="heading-3.1.14.2"></a>

##### 3.1.14.2 Location and Study Date

No evidence found.

<a id="heading-3.1.14.3"></a>

##### 3.1.14.3 Study Design

<a id="topic-3.1.14.3-1"></a>

###### Single-dose design

> “single-dose PK”

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="heading-3.1.14.4"></a>

##### 3.1.14.4 Eligibility Criteria

<a id="topic-3.1.14.4-1"></a>

###### Severe renal-impairment population

> “severe renal impairment”

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="heading-3.1.14.5"></a>

##### 3.1.14.5 Treatment

<a id="topic-3.1.14.5-1"></a>

###### Single oral dose

| Treatment | Dose |
| --- | --- |
| Saroglitazar, mg | “2” |

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="heading-3.1.14.6"></a>

##### 3.1.14.6 Study Outcomes

<a id="heading-3.1.14.6.1"></a>

###### 3.1.14.6.1 Rationale for Using Pharmacokinetic Parameters as the Primary Endpoint

Not applicable.

<a id="heading-3.1.14.7"></a>

##### 3.1.14.7 Statistical Analysis Description

<a id="heading-3.1.14.7.1"></a>

###### 3.1.14.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.14.7.1-1"></a>

###### Renal-impairment cohort and controls

| Population | Participants |
| --- | --- |
| Severe renal impairment | “eight” |
| Normal renal function controls | “eight” |

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="heading-3.1.14.7.2"></a>

###### 3.1.14.7.2 Description of Analysis Sets

<a id="topic-3.1.14.7.2-1"></a>

###### Pharmacokinetic analysis

> “non-compartmental”

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="heading-3.1.14.8"></a>

##### 3.1.14.8 Results

<a id="heading-3.1.14.8.1"></a>

###### 3.1.14.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.14.8.2"></a>

###### 3.1.14.8.2 Baseline Characteristics

<a id="topic-3.1.14.8.2-1"></a>

###### Baseline sex distribution

| Sex | Participants |
| --- | --- |
| Male | “eight” |
| Female | “eight” |

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="heading-3.1.14.8.3"></a>

###### 3.1.14.8.3 Efficacy Results

<a id="topic-3.1.14.8.3-1"></a>

###### Single-dose exposure relative to controls

> “comparable to matched controls”

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="heading-3.1.14.8.4"></a>

###### 3.1.14.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.14.8.5"></a>

###### 3.1.14.8.5 Safety Results

<a id="topic-3.1.14.8.5-1"></a>

###### Single-dose safety assessment

> “without significant safety issues”

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="heading-3.1.14.9"></a>

##### 3.1.14.9 Study Limitations

<a id="topic-3.1.14.9-1"></a>

###### Summary

This single-dose comparison included eight participants with severe renal impairment and eight controls. It does not establish repeated-dose safety, PBC efficacy, or dosing in participants with combined hepatic and renal impairment.

Source: [Vuppalanchi et al. (2025)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3450)

<a id="heading-3.1.15"></a>

#### 3.1.15 SARO.24.003

<a id="heading-3.1.15.1"></a>

##### 3.1.15.1 Objective

<a id="topic-3.1.15.1-1"></a>

###### Pharmacokinetic objective

> “pharmacokinetics, safety, and tolerability”

Source: [Veeva Systems SARO.24.003 study page](https://ctv.veeva.com/study/evaluating-pharmacokinetic-and-safety-of-saroglitazar-magnesium-1-mg-when-dosed-on-alternate-days-in)

<a id="heading-3.1.15.2"></a>

##### 3.1.15.2 Location and Study Date

No evidence found.

<a id="heading-3.1.15.3"></a>

##### 3.1.15.3 Study Design

<a id="topic-3.1.15.3-1"></a>

###### Open-label phase 1 design

> “A phase 1, open-label, single arm study”

Source: [Veeva Systems SARO.24.003 study page](https://ctv.veeva.com/study/evaluating-pharmacokinetic-and-safety-of-saroglitazar-magnesium-1-mg-when-dosed-on-alternate-days-in)

<a id="heading-3.1.15.4"></a>

##### 3.1.15.4 Eligibility Criteria

<a id="topic-3.1.15.4-1"></a>

###### Moderate hepatic impairment eligibility

| Criterion | Quoted value |
| --- | --- |
| Child-Pugh Turcotte score | “7 to 9” |

Source: [Veeva Systems SARO.24.003 study page](https://ctv.veeva.com/study/evaluating-pharmacokinetic-and-safety-of-saroglitazar-magnesium-1-mg-when-dosed-on-alternate-days-in)

<a id="heading-3.1.15.5"></a>

##### 3.1.15.5 Treatment

<a id="topic-3.1.15.5-1"></a>

###### Alternate-day regimen

| Regimen characteristic | Quoted value |
| --- | --- |
| Saroglitazar magnesium tablet strength | “1 mg” |
| Dosing schedule | “alternate days” |
| Duration | “29 days” |

Source: [Veeva Systems SARO.24.003 study page](https://ctv.veeva.com/study/evaluating-pharmacokinetic-and-safety-of-saroglitazar-magnesium-1-mg-when-dosed-on-alternate-days-in)

<a id="heading-3.1.15.6"></a>

##### 3.1.15.6 Study Outcomes

<a id="heading-3.1.15.6.1"></a>

###### 3.1.15.6.1 Rationale for Using Pharmacokinetic Parameters as the Primary Endpoint

Not applicable.

<a id="heading-3.1.15.7"></a>

##### 3.1.15.7 Statistical Analysis Description

<a id="heading-3.1.15.7.1"></a>

###### 3.1.15.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.15.7.1-1"></a>

###### Planned enrollment

| Population | Estimated participants |
| --- | --- |
| Single-arm pharmacokinetic study | “6” |

Source: [Veeva Systems SARO.24.003 study page](https://ctv.veeva.com/study/evaluating-pharmacokinetic-and-safety-of-saroglitazar-magnesium-1-mg-when-dosed-on-alternate-days-in)

<a id="heading-3.1.15.7.2"></a>

###### 3.1.15.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.15.8"></a>

##### 3.1.15.8 Results

<a id="heading-3.1.15.8.1"></a>

###### 3.1.15.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.15.8.2"></a>

###### 3.1.15.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.15.8.3"></a>

###### 3.1.15.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.15.8.4"></a>

###### 3.1.15.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.15.8.5"></a>

###### 3.1.15.8.5 Safety Results

No evidence found.

<a id="heading-3.1.15.9"></a>

##### 3.1.15.9 Study Limitations

<a id="topic-3.1.15.9-1"></a>

###### Summary

The planned study contains six participants and no randomized control group. It evaluates alternate-day administration in moderate hepatic impairment. The record provides no observed pharmacokinetic or safety results.

Source: [Veeva Systems SARO.24.003 study page](https://ctv.veeva.com/study/evaluating-pharmacokinetic-and-safety-of-saroglitazar-magnesium-1-mg-when-dosed-on-alternate-days-in)

## Related pages
- [Saroglitazar: Primary biliary cholangitis](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis.md)
- [Saroglitazar in Primary biliary cholangitis: Terms and abbreviations](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/terms-and-abbreviations.md)
- [Saroglitazar: Primary biliary cholangitis](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/executive-summary.md)
- [Saroglitazar in Primary biliary cholangitis: Product information and disease description](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/product-information-and-disease-description.md)
- [Saroglitazar in Primary biliary cholangitis: Economic information and modeling report](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/economics) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/economics.md)
- [Saroglitazar in Primary biliary cholangitis: References](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/references) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/references.md)
- [Saroglitazar in Primary biliary cholangitis: prevalence by geography](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/prevalence) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/prevalence.md)
- [Saroglitazar in Primary biliary cholangitis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/cost-effectiveness-analyses.md)
